New study aims to calm inflammation in preterm infants

NCT ID NCT07254000

Recruiting now Disease control Sponsor: Monash Medical Centre Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is for very premature babies (born between 24 and 29 weeks) to find the safest and most effective dose of a medicine called anakinra, which helps reduce inflammation. About 24 infants will receive anakinra through an IV or a shot under the skin. Researchers will measure how the drug moves through the body and check for early signs of lung and brain health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLAMMATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchopulmonary dysplasia Inflammation inflammatory disease Premature Birth

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLAMMATION PREMATURE INFANTS VERY PREMATURE INFANTS

Contacts and locations

Locations

Monash Children's Hospital
RECRUITING

Clayton, Victoria, 3168, Australia
Starship Children's Hospital
NOT_YET_RECRUITING

Grafton, Auckland, 1023, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.